EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ANTI–TUBERCULAR AND NON-TUBERCULAR DRUGS AMONG PATIENTS WITH PULMONARY TUBERCULOSIS IN PUDUCHERRY AND TAMIL NADU

Cathrine John Marie, Senbagavalli PB*, Komala Ezhumalai, Selby Knudsen2, C. Robert Horsburgh, Natasha S. Hochberg, Padmini Salgame, Jerrold Ellner, Sonali Sarkar

ABSTRACT

Tuberculosis (TB) demands a long-term multi-drug treatment. Co-infection in TB patients and concomitant noninfectious disease, particularly with an aging population, undoubtedly necessitates the use of additional drugs. This multi-drug management in a TB population increases the potential for drug interactions. The study focus is to perform a comprehensive analysis of the prevalence of and factors associated with potential interactions of first-line Anti Tubercular Therapy (ATT) drugs and concomitant medications among patients with pulmonary tuberculosis. Newly diagnosed pulmonary TB patients undergoing the standard directly observed treatment short-course (DOTS) 6-month regimen (N=205) enrolled after September 2017 were included in the study. The ATT drugs and the concomitant drugs were checked for their possible drug-drug interactions with their categorization by utilizing the IBM Micromedex solutions online database. Fifty eight patients (28.3%) were taking ATT with other concomitant medications. The most common concomitant medications were oral hypoglycemic drug metformin (75.9%) followed by glimepiride (43.1%) Prevalence of potential drug-drug interactions among the participants were 23.4% (95%CI: 17.8%-29.8%). There were 24 common drug interactions with 19 interactions having potential impact on non-ATT drugs and 5 having potential impact on ATT drugs. The majority (58.4%) of these interactions were moderate followed by major (33.3%) and minor (8.3%). Careful consideration and appropriate use of drugs, thereby avoiding the incidence of drug interactions, is an essential step in mitigation of the effects of complications.

Keywords: Drug-drug Interactions, Anti-tubercular drugs, Concomitant medication, Tuberculosis, Pulmonary tuberculosis.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • EJPMR JANUARY ISSUE PUBLISHED

    JANUARY Issue has been successfully launched on 1 January 2021.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2020 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR NOVEMBER ISSUE PUBLISHED

    NOVEMBER 2020 Issue has been successfully launched on 1 November 2020.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )